Intangibles, net, consisted of the following:


	September 30, 2026
(in thousands)	Useful Lives (in years)	Amortization Method	Gross		Accumulated Amortization			Net
Amortizable:
Trademarks	25	Straight-line	$	13,540	$	(12,620	)	$	920
Customer relationships	5	Accelerated		102,844		(97,331	)		5,513
Currently marketed products	9 - 10.5	Straight-line		492,800		(119,794	)		373,006
Licenses	13 - 16	Straight-line		22,233		(14,890	)		7,343
Developed technology	7 - 9	Straight-line		55,982		(19,152	)		36,830
Total amortizable intangibles				687,399		(263,787	)		423,612
Non-amortizable:
In-process research and development	Indefinite			218,000		—			218,000
Total intangibles, net			$	905,399	$	(263,787	)	$	641,612


	December 31, 2025
(in thousands)	Useful Lives (in years)	Amortization Method	Gross		Accumulated Amortization			Net
Amortizable:
Trademarks	25	Straight-line	$	13,540	$	(12,509	)	$	1,031
Customer relationships	5	Accelerated		102,958		(90,834	)		12,124
Currently marketed products	9 - 10.5	Straight-line		492,800		(83,013	)		409,787
Licenses	13 - 16	Straight-line		22,233		(14,167	)		8,066
Developed technology	7 - 9	Straight-line		55,982		(13,211	)		42,771
Total amortizable intangibles				687,513		(213,734	)		473,779
Non-amortizable:
In-process research and development	Indefinite			249,000		—			249,000
Total intangibles, net			$	936,513	$	(213,734	)	$	722,779

During the third quarter of 2026, the Company identified an impairment triggering event on its LNTH-2620 (previously referred to as PI-2620) and LNTH-2515 in-process research and development (“IPR&D”) intangible assets, and after completing the quantitative impairment test, recognized impairment charges of $21.0 million and $10.0 million, respectively. LNTH-2620 and LNTH-2515 were acquired in July 2025 with the acquisition of Lantheus Biosciences and had initial fair values of $21.0 million and $13.0 million, respectively, based on expected future cash flows on the date of acquisition. The impairment charges for LNTH-2620 and LNTH-2515 are included in research and development (“R&D”) expenses in the Company’s condensed consolidated statements of operations for the three and nine months ended September 30, 2026.

On August 14, 2026, the Company announced that the FDA approved TAUKLARIFY (florquinitau F-18 injection), also referred to as MK-6240. As a result, the Company reassessed the existing development plan for LNTH-2620 and because there is no near-term plan to commercialize the asset, the Company determined that based on the updated analysis of the future cash flow, the value of the asset that remained was immaterial and therefore the Company recorded the full impairment in an amount equal to $21.0 million for the three and nine months ended September 30, 2026.

During the third quarter of 2026, the Company performed an updated analysis of the future cash flows of LNTH-2515 and as a result, recognized an impairment charge of $10.0 million during the three and nine months ended September 30, 2026.

The estimate of future cash flows used in impairment testing involves significant management judgment, and is based upon assumptions about expected future operating performance, economic conditions, market conditions and cost of capital. Inherent in estimating the future cash flows are uncertainties beyond our control, such as changes in capital markets. The actual cash flows could differ materially from management’s estimates due to changes in business conditions.

The Company recorded amortization expense for its intangible assets of $16.7 million and $14.6 million for the three months ended September 30, 2026 and 2025, respectively, and $50.2 million and $30.6 million for the nine months ended September 30, 2026 and 2025, respectively.